93125-79-2 Usage
General Description
N-Cyclohexyl 3-nitrobenzenesulfonamide, also known as N-(Cyclohexylsulfonyl)-3-nitrobenzenesulfonamide, is a chemical compound commonly used in the pharmaceutical industry as a carbonic anhydrase inhibitor. It is a derivative of sulfonamide and has been studied for its potential therapeutic applications, particularly in the treatment of glaucoma, epilepsy, and certain types of cancer. N-CYCLOHEXYL 3-NITROBENZENESULFONAMIDE has shown promising results in reducing intraocular pressure and is also being explored for its potential anti-tumor and anticonvulsant properties. Additionally, it is utilized in the synthesis of various other pharmaceuticals and biologically active compounds. Despite its potential therapeutic applications, N-cyclohexyl 3-nitrobenzenesulfonamide also poses some health risks and precautions should be taken in handling and using this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 93125-79-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,1,2 and 5 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 93125-79:
(7*9)+(6*3)+(5*1)+(4*2)+(3*5)+(2*7)+(1*9)=132
132 % 10 = 2
So 93125-79-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N2O4S/c15-14(16)11-7-4-8-12(9-11)19(17,18)13-10-5-2-1-3-6-10/h4,7-10,13H,1-3,5-6H2
93125-79-2Relevant articles and documents
Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)
Vandyck, Koen,Rombouts, Geert,Stoops, Bart,Tahri, Abdellah,Vos, Ann,Verschueren, Wim,Wu, Yiming,Yang, Jingmei,Hou, Fuliang,Huang, Bing,Vergauwen, Karen,Dehertogh, Pascale,Berke, Jan Martin,Raboisson, Pierre
supporting information, p. 6247 - 6260 (2018/06/25)
Small molecule induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.
